Meng Min, Li Wenhong, Yang Xia, Huang Guanghui, Wei Zhigang, Ni Yang, Han Xiaoying, Wang Jiao, Ye Xin
Department of Oncology, Shandong Provincial Hospital Affiliated, Shandong First Medical University, Jinan, China.
Department of Oncology, The First Affiliated Hospital of Shandong First Medical University, 16766 Jingshi Road, Jinan, Shandong Province 250014, China.
J Cancer Res Ther. 2020;16(2):327-334. doi: 10.4103/jcrt.JCRT_101_20.
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. Currently, the main effective treatment options for HCC include resection, liver transplantation, various percutaneous modalities (such as transarterial chemoembolization [TACE] and thermal ablation), and tyrosine kinase inhibitors (TKIs). Herein, we have proposed a novel therapy which consists of TACE, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI) for patients with advanced HCC). We reported the therapeutic effects of TATI in four patients with advanced HCC. All patients underwent TACE treatment at the beginning of disease diagnosis. During follow-up, all patients were treated with microwave ablation because of a residual tumor or recurrence. For tumor control, apatinib, a TKI, was administered after ablation. If the tumor was resistant to the TKI, we continued to apatinib therapy in combination with immunotherapy (camrelizumab). All the four patients had better survival benefits and no serious adverse effects.
肝细胞癌（HCC）是最常见的恶性肿瘤之一。目前，HCC的主要有效治疗选择包括手术切除、肝移植、各种经皮治疗方式（如经动脉化疗栓塞术[TACE]和热消融）以及酪氨酸激酶抑制剂（TKIs）。在此，我们提出了一种针对晚期HCC患者的新型治疗方法，该方法由TACE、消融、酪氨酸激酶抑制剂和免疫疗法（TATI）组成。我们报告了TATI对4例晚期HCC患者的治疗效果。所有患者在疾病诊断开始时均接受了TACE治疗。在随访期间，所有患者因残留肿瘤或复发接受了微波消融治疗。为了控制肿瘤，消融后给予TKI阿帕替尼。如果肿瘤对TKI耐药，我们继续使用阿帕替尼联合免疫疗法（卡瑞利珠单抗）治疗。所有4例患者均获得了更好的生存获益且无严重不良反应。
